EUVIMEDEUVIMED entdecken
Crossref

Pharmacological induction of mitochondria-lysosome hyper-tethering elicits synthetic lethality in glioblastoma

Dongyuan Su, Yanping Huang, Biao Hong, Xiaoteng Cui, Jixing Zhao, Qi Zhan, Kaikai Yi, Yaqing Ding, Hanyi Xu, Qixue Wang, Hongbo Guo, Chunsheng Kang

Cancer Letters · 2026-08 · 654 · 218615

DOI: 10.1016/j.canlet.2026.218615 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-08. Verfasst von Dongyuan Su und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Tianjin Medical University General Hospital, Laboratory of Neuro-oncology, Tianjin Neurological Institute, Key Laboratory…. Hauptthemen laut MEDLINE: Glioblastoma, Lysosomes, Mitochondria, Quinacrine. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Special Project for Research and Development in Key areas of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical translation of synthetic lethality between cytoplasmic phospholipase A2 (cPLA2) and dipeptidyl peptidase 4 (DPP4) in glioblastoma (GBM) has been hindered by the absence of clinically applicable cPLA2 inhibitors. In this study, we demonstrate that quinacrine, a clinically available drug with cPLA2 inhibitory activity, synergizes with the DPP4 inhibitor linagliptin to exert potent anti-tumour effects. This combination synergistically depleted mitochondrial proteins, and inhibited GBM growth, significantly prolonging survival compared with temozolomide. Mechanistically, quinacrine promoted p62-dependent autophagic degradation of both cPLA2 and the mitochondrial fission protein FIS1, while linagliptin disrupted a DPP4-EGFR positive feedback loop, impairing EGFR-mediated phosphorylation of RAB7 at Ser72 and thereby stabilizing GTP-bound RAB7. These parallel inhibitions converged to enhance the frequency and duration of mitochondria-lysosome contacts, leading to massive mitochondrial degradation and bioenergetic collapse through a process termed mitochondria-lysosome hyper-tethering (MLHT). Furthermore, we established a composite transcriptional signature (DPP4-CPLA2-FIS1, DCF score) that reflects axis activity and enables metabolic stratification and therapeutic guidance for GBM. Our work not only presents a clinically feasible strategy for GBM treatment but also redefines the synthetic lethal interaction by shifting the target pair from cPLA2-DPP4 to the effector pair FIS1-RAB7, establishing hyper-activated mitochondria-lysosome tethering as a druggable anti-tumour mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaLysosomesMitochondriaQuinacrineBrain NeoplasmsHumansAnimalsCell Line, Tumorrab7 GTP-Binding Proteinsrab GTP-Binding ProteinsMiceTemozolomideAutophagyXenograft Model Antitumor AssaysDrug Synergism

Stichwörter der Autor:innen

LinagliptinMitochondria collapseMitochondria-lysosome hyper-tethering (MLHT)QuinacrineSynthetic lethality

Substanzen

Quinacrinerab7 GTP-Binding Proteinsrab GTP-Binding Proteinsrab7 GTP-binding proteins, humanTemozolomide

Autor:innen und Institutionen

  • Department of Neurosurgery, Tianjin Medical University General Hospital, Laboratory of Neuro-oncology, Tianjin Neurological Institute, Key Laboratory of Post-Neuro Injury Neuro-Repair and Regeneration in Central Nervous…
  • Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, 100…
  • Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, Shandong, 250012, China.
  • Department of Neuro-Oncology and Neurosurgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin'…
  • Department of Neurosurgery Center, The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China on Diagnosis and Treatment of Cerebrovascular Disease, Guangdong Provinci…

Förderung

  • Special Project for Research and Development in Key areas of Guangdong Province

Zitieren

APA

Su, D., Huang, Y., Hong, B., Cui, X., Zhao, J., Zhan, Q., Yi, K., Ding, Y., Xu, H., Wang, Q., Guo, H., & Kang, C. (2026). Pharmacological induction of mitochondria-lysosome hyper-tethering elicits synthetic lethality in glioblastoma. Cancer Letters, 654, 218615. https://doi.org/10.1016/j.canlet.2026.218615

Vancouver

Su D, Huang Y, Hong B, Cui X, Zhao J, Zhan Q, et al. Pharmacological induction of mitochondria-lysosome hyper-tethering elicits synthetic lethality in glioblastoma. Cancer Letters. 2026;654:218615. doi:10.1016/j.canlet.2026.218615

BibTeX
@article{Su2026,
  author = {Su, Dongyuan and Huang, Yanping and Hong, Biao and Cui, Xiaoteng and Zhao, Jixing and Zhan, Qi and Yi, Kaikai and Ding, Yaqing and Xu, Hanyi and Wang, Qixue and Guo, Hongbo and Kang, Chunsheng},
  title = {Pharmacological induction of mitochondria-lysosome hyper-tethering elicits synthetic lethality in glioblastoma},
  journal = {Cancer Letters},
  year = {2026},
  volume = {654},
  pages = {218615},
  doi = {10.1016/j.canlet.2026.218615}
}
Kostenlos starten →